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ABSTRACT We have established a growth selection re-
quirement for a catalytic antibody with modest chorismate
mutase activity. Conversion of (-) chorismate into prephenate
is the key step in the biosynthesis of the aromatic amino acids
tyrosine and phenylalanine. Strains of the yeast Saccharomyces
cerevisiae containing an insertion mutation in the structural
gene for the enzyme chorismate mutase (EC 5.4.99.5) require
exogenous supplements of these two amino acids for efficient
growth. Intracellular expression of the heterologous antibody
catalyst in one such strain, identified by random nutagenesis
and genetic selection, provides a substantial growth advantage
under auxotrophic conditions; complementation was not ob-
served with an unrelated esterolytic antibody. In addition to
demonstrating that tailored immunoglobulin catalysts can
carry out vital biochemical reactions in vivo, these experiments
provide a powerful selection assay for identifying genetic
changes within the antibody molecule itself that augment
chemical efficiency.
Antibodies generated against appropriately designed transi-
tion state analogs catalyze a wide variety of chemical trans-
formations (1, 2). Like naturally occurring enzymes, catalytic
antibodies achieve substantial rate accelerations with high
regio- and stereoselectivity under mild aqueous conditions.
As both the mechanism and recognition properties of immu-
noglobulin catalysts are defined by the structure of the
immunizing antigen, this technology provides a potentially
general method for preparing tailored enzyme-like molecules
on demand for practical applications in chemistry, biology,
and medicine. For example, the specificity and biocompati-
bility of catalytic antibodies suggest that they might be useful
for effecting important chemical transformations in vivo.
Here we demonstrate the feasibility of this proposition by
showing that an antibody with modest chorismate mutase
(EC 5.4.99.5) activity (3) can function inside a yeast cell
lacking the natural enzyme and confer a growth advantage to
its host by virtue of its catalytic activity.
MATERIALS AND METHODS
Antibody Expression. The genes encoding the catalytic
antibody 1F7 were expressed as described (4) using plasmid
pABZ260 and the chorismate mutase-deficient Saccharomy-
ces cerevisiae strain YT-4Ca (MATa, aro7::HIS3, leu2,
ura3). Plasmid pABZ265, carrying the genes encoding the
esterolytic catalytic antibody 6D4 (5, 6), served as a control
(see Fig. 2).
In Vitro Mutagenesis and Selection. Cells transformed with
pABZ260 were subjected to random mutagenesis with ethyl
methanesulfonate according to standard procedures (7). Sur-
vival after mutagenesis was -20%6. Approximately 5 X 109
mutagenized cells were spread on solid yeast extract/
peptone/dextrose medium, allowed to grow at 300C for 2
days, and replicated onto tyrosine dropout plates containing
2% galactose. Colonies that appeared under selective condi-
tions were picked and plated on phenylalanine dropout plates
containing 2% galactose in order to isolate single colonies.
Purified mutants were tested for the presence of plasmid by
colony hybridization (8) and for expression of functional
antibody by ELISA (9).
Analysis of Mutants. Individual mutants were tested for
segregation ofthe Phe+ growth phenotype with the antibody-
bearing plasmid (7). Segregants were identified by patching
cells on 1% yeast extract/2% peptone/2% galactose plates to
allow plasmid loss, then streaking for single colonies, and
printing on synthetic minimal plates with 2% galactose but
lacking either leucine or phenylalanine, Auxotrophy for
leucine, phenylalanine, tyrosine, and uracil was verified on
the corresponding selection plates. Plasmid DNA was recov-
ered from individual mutants by transforming Escherichia
coli strain DH5a with total yeast DNA and selecting for
ampicillin-resistant (Ampr) transformants. DNA samples
were then characterized by sizing gel electrophoresis and
restriction mapping. Mutagenized and unmutagenized plas-
mids were reintroduced into the original and mutagenized
mutase-negative yeast strains, and the resulting transform-
ants were assayed under selective conditions in liquid culture
and on agar plates.
RESULTS AND DISCUSSION
Carlson (10) demonstrated a number of years ago that func-
tional antibody molecules can be expressed cytoplasmically
in yeast to alter phenotype. An engineered strain of S.
cerevisiae containing an antibody directed against yeast
alcohol dehydrogenase was shown to exhibit increased
growth on allyl alcohol due to limited neutralization of the
target enzyme by the immunoglobulin. We wondered
whether it would be possible to extend this work and exploit
antibodies as tailored intracellular catalysts rather than sim-
ply as receptors.
Our efforts to date have focused on the shikimate pathway
for the biosynthesis ofaromatic amino acids in yeast (11). The
conversion of (-)-chorismate into prephenate, a formal ali-
phatic Claisen rearrangement, is the committed step toward
production ofphenylalanine and tyrosine in this scheme (Fig.
1). The enzyme chorismate mutase enhances the rate of this
reaction by >106-fold over the uncatalyzed thermal process
(12). In S. cerevisiae, chorismate mutase is a monofunctional,
cytoplasmic protein consisting of two identical subunits (Mr,
30,000). Its structural gene, ARO7, has been cloned, and
mutations in it confer auxotrophy for tyrosine and phenyl-
alanine (13, 14).
Antibodies with chorismate mutase activity have been
elicited with a compound that mimics the putative high-
energy transition state for the rearrangement of chorismate
into prephenate (3, 15, 16). We recently expressed the genes
encoding the Fab protein fragment of one of these antibodies
(1F7) in the engineered yeast strain YT-4Ca, which lacks
natural chorismate mutase activity (4). The antibody gene
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FIG. 1. Shikimate pathway for biosynthesis of aromatic amino
acids in yeast. AR07 encodes the enzyme chorismate mutase, which
promotes the rearrangement of chorismate into prephenate.
segments (minus the signal sequences) were inserted into an
inducible expression vector under the control of the GALI-
GALIO promoters (pABZ260; Fig. 2). Galactose induction of
cells transformed with pABZ260 produced high levels of
correctly assembled Fab in the host's cytoplasm. We esti-
mated that the intracellular concentration of 1F7 corre-
sponded to 0.1% of the total cellular protein in these trans-
formants, =10 times higher than the concentration of cho-
rismate mutase in wild-type cells (12). However, the Fab
isolated from yeast exhibited the same specific activity in
vitro as the hybridoma-derived immunoglobulin-i.e., a 200-
fold rate acceleration over background (3)-and rescue ofthe
host's chorismate mutase deficiency was not observed (4).
Successful complementation of a genetic defect with a
heterologous antibody catalyst is likely to depend on many
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FIG. 2. High copy number yeast plasmid for expression of the
Fab protein fragment of the chorismate mutase antibody 1F7
(pABZ260). The plasmid was constructed as described (4); H and L
represent truncated heavy- and light-chain antibody coding genes of
1F7, respectively. The leu2-d gene serves as a selectable marker, and
at and FLPt correspond to the 3'-transcriptional termination signals
of the MFa1 and FLP genes. Plasmid pABZ265 is an identical
construct except that H and L are replaced by the respective
truncated heavy- and light-chain coding genes for the esterolytic
antibody 6D4 (5, 6).
interrelated factors, including catalytic turnover, level of
expression, protein assembly and half-life, and cellular lo-
calization. To isolate a chorismate mutase-deficient yeast
strain capable of being rescued by 1F7 we have used muta-
genesis with ethyl methanesulfonate and genetic selection. A
screen of 109 mutants generated by treating antibody-
harboring YT4Ca cells with ethyl methanesulfonate (7)
yielded 298 colonies that grew under auxotrophic conditions.
One of these mutants, designated 351m::1F7*, was charac-
terized in some detail and shown to require the activity of 1F7
for growth in the absence of exogenous tyrosine and phen-
ylalanine.
Several lines of evidence demonstrate that the chorismate
mutase antibody plays an essential metabolic role in
351m::1F7*. First, the Phe', Tyr' phenotype segregates with
the antibody-bearing plasmid. Strain 351m, obtained from
351m::1F7* after segregation and lacking the antibody-
encoding plasmid, grows poorly under auxotrophic condi-
tions. In liquid medium without phenylalanine, for example,
the difference in growth rate between 351m::1F7* and 351m
is striking (Fig. 3). The antibody-containing strain grows into
stationary phase at 65 hr, achieving a final cell density of 8.8
X i07 cells per ml. Its doubling time in logarithmic phase is
-6 hr. In contrast, strain 351m only reached a cell density of
2.5 x 10 cells per ml after 72 hr and did not exhibit
logarithmic-phase growth. Qualitatively similar results were
obtained on agar selection plates (Fig. 4A).
The second observation supporting the functional signifi-
cance of intracellularly expressed 1F7 is that 351m::1F7*
requires galactose as a carbon source for growth under
selective conditions (Fig. 4A). When glycerol is used instead,
no selective growth advantage over strain 351m is observed
(Fig. 4B). Glycerol itself is not harmful to the cells, as both
strains grow normally on glycerol when phenylalanine and
tyrosine are supplied (Fig. 4C). These results indicate that the
GALJ-GAL10 promoters controlling transcription of the
antibody-encoding genes must be activated in order to
achieve complementation. We confirmed by an independent
ELISA that antibody protein is produced in cells containing
the (lF7)Fab expression plasmid only upon galactose induc-
tion.
Finally, and most importantly, we were able to show that
serial transformation of the mutant yeast strain allowed
reconstitution of its defective shikimate pathway. Yeast
cells, transformed with either the plasmid recovered from the
351m::1F7* cells (351m::1F7*1) or the original 1F7 expres-
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FIG. 3. Growth curves for yeast strains 351m::lF7* (0), 351m
(o), and YT-4Ca (o) under selective conditions. Each strain was
grown at 30°C in 5 ml of liquid medium containing 2% galactose but
lacking phenylalanine from a starting concentration of 5 x 106 cells
per ml. Cell density was determined by counting cells with a
hemacytometer.
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FIG. 4. Test of complementation on selective agar plates. The
plates contained 0.67% Difco yeast nitrogen base, the necessary
nucleotides and amino acids except (-Phe) or including (+Phe)
phenylalanine, and 2% galactose (Galactose) or 3% glycerol plus 3%
ethanol (Glycerol). The permissive yeast host strain 351m was
derived from the mutant 351m::1F7* by loss of the antibody-bearing
plasmid. Transformation of 351m with plasmids pABZ260 and
pABZ265 gave strains 351m::1F7 and 351m::6D4, respectively,
where 1F7 refers to the chorismate mutase antibody and 6D4 is an
unrelated catalytic antibody with esterolytic activity. Transforma-
tion of YT-4Ca and 351m with the plasmid recovered from
351m::1F7* yielded strains YT4Ca::1F7* and 351m::1F7*¶e, respec-
tively. The plate in C was incubated at 25°C for 4 days and stored at
4°C before photography, while the plates in A and B were incubated
at 25°C for 10 days.
sion plasmid pABZ260 (351m::1F7), are able to grow under
auxotrophic conditions (Fig. 4A). In contrast, transformation
of yeast cells with the control plasmid, pABZ265 (Fig. 2),
which carries the Fab coding sequence for the unrelated
esterolytic antibody 6D4 (5, 6), does not suppress the aro7
mutation (351m: :6D4; Fig. 4A). Clearly, expression of large
amounts of immunoglobulin protein within the cell is not
sufficient for complementation; an antibody with the correct
active site and chemical reactivity is required.
It is important to note that the chemical efficiency of the
chorismate mutase antibody has not been increased as a
result of the mutagenesis experiments: transformation of the
parent YT-4Ca strain with plasmid recovered from
351m::1F7* does not produce cells capable of growth under
selective conditions (YT-4Ca::lF7*, Fig. 4A). Rather, 351m
is a permissive host strain. The nature of the genomic
mutation(s) that facilitates complementation by the catalytic
antibody remains to be investigated and may reflect either
improved intracellular expression and/or stability of the
immunoglobulin. The slight growth advantage observed for
351m compared to the unmutagenized starting strain YT-4Ca
(Fig. 3) is also consistent with an elevated intracellular
concentration of chorismate and hence a higher rate for the
spontaneous thermal rearrangement, in which case the anti-
body would only have to supply modest additional activity to
the cell to reach the threshold level needed for growth.
Additional improvements in expression or efficiency of 1F7
are expected to increase the selective advantage of the
+Phe. Glycerol
antibody-containing cells still further. Indeed, the growth
requirement that has been established for antibody activity
can now be exploited to evaluate genetic changes in the
immunoglobulin molecule itself. Through subsequent rounds
of random mutagenesis and genetic selection, for example, it
may be possible to augment MF7's catalytic potency directly
(17). The use of biological selection pressure in this way to
direct the evolution of immunoglobulin catalysts would have
great significance, given that first-generation catalytic anti-
bodies are typically orders of magnitude less efficient than
naturally occurring enzymes.
In sum, we have shown that a catalytic antibody can
function in vivo to complement a defective biosynthetic
pathway in a permissive strain of the yeast S. cerevisiae.
These experiments thus establish the feasibility of directing
eukaryotic cells to produce man-made catalysts not normally
found in their evolutionary repertoire. In principle, entirely
new catalytic functions can now be engineered into such
cells, since tailored immunoglobulin catalysts can be pre-
pared for a wide range of chemical reactions, including
transformations without known biological counterparts (18).
We anticipate that expression of functional antibody cata-
lysts in living organisms will provide exciting opportunities
for regulating cellular function, altering cellular metabolism,
and destroying toxins in vivo.
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